Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 4 patents granted in the last 365 days
Shenzhen Technology University currently has 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This action is situated within 1 distinct art unit, reflecting a focused technical engagement with the USPTO in a specific area of biotechnology. The university's current prosecution activity is concentrated in this single matter, rather than being spread across multiple technical disciplines. The 1 distinct art units involved provide a concentrated technical environment for the examination of the university's current innovations.
The prosecution is overseen by 1 distinct examiners, with BAUER, BRIANNA LEE serving as the busiest examiner. BAUER, BRIANNA LEE is responsible for 1 busiest examiner pending office action, which constitutes the total active workload for the portfolio. This one to one relationship between the 1 pending office action and the examiner allows for a very direct and focused communication strategy. For practitioners, the presence of 1 distinct examiners means that the immediate success of the portfolio depends on a single examination cycle.
There is no need to manage multiple art unit standards or different examiner preferences across this portfolio. The focus remains entirely on the 1 distinct art units involved and the specific feedback provided by BAUER, BRIANNA LEE in the Biotechnology & Pharmaceuticals sector. With 1 busiest examiner pending, the applicant can expect a consistent application of examination guidelines. This concentration in a single technical area highlights the university's primary research focus, while the 1 distinct examiners assigned simplifies the overall management of the prosecution cycle.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BAUER, BRIANNA LEE | 1 | 66.7% | +0.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18780670 | USE OF DOXEPIN HYDROCHLORIDE IN PREPARATION OF ANTIVIRAL DRUG | BAUER, BRIANNA LEE | — |
| Art Unit | Apps |
|---|---|
| 1623 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18780670 | USE OF DOXEPIN HYDROCHLORIDE IN PREPARATION OF ANTIVIRAL DRUG | BAUER, BRIANNA LEE | 1623 | §101§103§112 | Non-Final OA | — | Pending | Jul 23, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialShenzhen Technology University has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Brianna Lee Bauer has the most, with 1 of Shenzhen Technology University's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
